12 completed, 3 recruiting, 1 unknown. 16 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 12, Recruiting 3, Unknown 1 |
| Phase 2 | 7 | Completed 7 |
Follow Nerve Degeneration: new trials by email Literature Review of Nerve Degeneration trials Research Report on Nerve Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD) [¹⁸F]MK-0947 - Parkinsons Disease (PD), Healthy Elderly Volunteers | Phase 1 | Recruiting | XingImaging, LLC | 18 | 2026-08-25 | 2026-10-19 |
| AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980) AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg - Alzheimer Disease, Preclinical Alzheimer's Disease | Phase 1 | Recruiting | Institute for Molecular Medicine | 48 | 2026-06-23 | 2026-08-21 |
| Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease Kisspeptin 112-121 - Reproductive Disorder, Neurodegeneration | Phase 1 | Recruiting | Stephanie B. Seminara, MD | 40 | 2026-03-10 | 2026-07-13 |
| Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg - Covid19, Corona Virus Infection | Phase 1 | Unknown | Biomed Industries, Inc. | 45 | 2020-09-15 | 2020-07-21 |
| Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder dextromethorphan and memantine (DM+MM), Placebos - Stimulants Use Disorder | Phase 1 / Phase 2 | Completed | Tzu-Yun Wang | 85 | 2018-07-24 | 2020-12-10 |
| A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease [18F]THK-5351 - Alzheimer Disease | Phase 1 | Completed | Asan Foundation | 12 | 2017-05-17 | 2020-12-14 |
| Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease VTS-270 - Niemann-Pick Disease, Type C1 | Phase 1 | Completed | Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company | 14 | 2013-01-01 | 2021-07-23 |
| Neuroregenerative Potential of Intravenous G-CSF and Autologous Peripheral Blood Stem Cells Peripheral blood mononuclear cells (mPBMC), G-CSF, Placebo - Neurodegeneration, G-CSF | Phase 1 / Phase 2 | Completed | Hanyang University Seoul Hospital | 57 | 2011-08-01 | 2016-12-07 |
| Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. MSC-NTF cells transplantation (IM), MSC-NTF cells transplantation (IT) - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Completed | Brainstorm-Cell Therapeutics | 12 | 2011-06-01 | 2019-01-10 |
| Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy alpha-lipoic acid and L-acetyl carnitine - Progressive Supranuclear Palsy | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 11 | 2010-09-14 | 2017-05-30 |
| Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine N-Acetyl Cysteine - Niemann-Pick Disease, Type C | Phase 1 / Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 35 | 2009-08-01 | 2013-05-06 |
| Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) epigallocatechin-gallate (Sunphenon), placebo - Relapsing-remitting Multiple Sclerosis | Phase 1 / Phase 2 | Completed | Charite University, Berlin, Germany | 120 | 2007-09-01 | 2021-07-29 |
| Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED) A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine, B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg, C: MK-3134 25 mg + Scopolamine 0.5 mg - Dementia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 31 | 2007-06-01 | 2015-11-06 |
| Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia Idebenone - Friedreich Ataxia | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 16 | 2004-02-01 | 2008-03-04 |
| Safety Study of Idebenone to Treat Friedreich's Ataxia Idebenone - Friedreich Ataxia | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 100 | 2001-05-01 | 2006-07-12 |
| Copper Histidine Therapy for Menkes Diseases Copper Histidine - Kinky Hair Syndrome | Phase 1 / Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 60 | 1990-06-01 | 2015-10-30 |
Alzheimer Disease (2) · Cognitive Dysfunction (2) · Friedreich Ataxia (2) · Inflammation (2) · Niemann-Pick Disease, Type C (2) · Amyotrophic Lateral Sclerosis (1) · COVID-19 (1) · Cerebral Palsy (1) · Coronavirus Infections (1) · Dementia (1) · Frontotemporal Dementia (1) · Menkes Kinky Hair Syndrome (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Nervous System Diseases (14) · Central Nervous System Diseases (12) · Brain Diseases (11) · Metabolic Diseases (7) · Neurodegenerative Diseases (7) · Nutritional and Metabolic Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Mental Disorders (4) · Neurocognitive Disorders (4) · Brain Diseases, Metabolic (3) · Brain Diseases, Metabolic, Inborn (3) · Heredodegenerative Disorders, Nervous System (3)
idebenone (2) · 2-Hydroxypropyl-beta-cyclodextrin (1) · Acetylcarnitine (1) · Acetylcysteine (1) · Dextromethorphan (1) · Donepezil (1) · Granulocyte Colony-Stimulating Factor (1) · Memantine (1) · Scopolamine (1) · Sunphenon (1) · THK5351 (1) · Thioctic Acid (1) · copper histidine (1) · epigallocatechin gallate (1) · remdesivir (1)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Asan Foundation (1) · Biomed Industries, Inc. (1) · Brainstorm-Cell Therapeutics (1) · Charite University, Berlin, Germany (1) · Hanyang University Seoul Hospital (1) · Institute for Molecular Medicine (1) · Merck Sharp & Dohme LLC (1) · Stephanie B. Seminara, MD (1) · Tzu-Yun Wang (1) · Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company (1) · Weill Medical College of Cornell University (1) · XingImaging, LLC (1)
United States (10) · Germany (1) · Israel (1) · South Korea (1) · Taiwan (1)
Claire Henchcliffe, MD DPhil (1) · Dimitrios Karussis, MD, PhD (1) · Forbes D Porter, M.D. (1) · Friedemann Paul, Prof., MD (1) · JaeEun Kim (1) · Judith Bellmann-Strobl, Dr., MD (1) · Lloyd Tran, PhD (1) · Michael Agadjanyan, PhD (1) · Neha Parkash, MBBS (1) · Roman Kniazev (1) · Stephen G Kaler, M.D. (1) · Tzu-Yun Wang (1)
PMID 17562928, PMID 15923132, PMID 16278898, PMID 17482283, PMID 18256395, PMID 18752978, PMID 19194885, PMID 20497190, PMID 20652413, PMID 21644059, PMID 22134099, PMID 25281031, PMID 26751635, PMID 28109298, PMID 31187454, PMID 33762428, PMID 34810067, PMID 40525490, PMID 7842019, PMID 8295415, PMID 8419622, PMID 8526465, PMID 8812725
R01AG092949 (1), R37HD043341 (1)